Trial Profile
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Mavoglurant (Primary)
- Indications Cocaine-related disorders
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 17 Dec 2019 Planned End Date changed from 8 Jan 2020 to 20 Dec 2019.
- 17 Dec 2019 Planned primary completion date changed from 8 Jan 2020 to 20 Dec 2019.